Logo

OmniSeq Immune Report Card

Jun 14, 2017

OmniSeq has launched its Immune Report Card, an immune profiling test designed to help oncologists select the best mono and combination immunotherapy options for patients. The assay integrates five clinical-grade tests that together provide a comprehensive immune profile. The report card includes CD3/8 and PD-L1 immunohistochemistry, PD-L1/2 copy number using in situ hybridization, microsatellite instability testing, mutational burden analysis via Thermo Fisher Scientific's Ion Torrent next-generation sequencing of 409 exon cancer genes, and cross-validated simultaneous gene expression analysis of 54 critical transcripts via targeted RNA-seq using the Oncomine Immune Response Research Assay. The test is approved by the New York State Clinical Laboratory Evaluation Program, the company said.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.